These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25506379)

  • 1. Recent advances in personalized lung cancer medicine.
    Okimoto RA; Bivona TG
    Per Med; 2014; 11(3):309-321. PubMed ID: 25506379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Which platform to support a personalized lung cancer treatment?].
    Ruppert AM; Antoine M; Beau-Faller M; Cadranel J; Wislez M
    Bull Cancer; 2012 May; 99(5):529-34. PubMed ID: 22525302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSCLC and HER2: between lights and shadows.
    Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
    J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations.
    Milano GA
    Chin Clin Oncol; 2015 Dec; 4(4):47. PubMed ID: 26730759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
    Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
    Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
    Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
    J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
    Lee DH
    Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future options for ALK-positive non-small cell lung cancer.
    Iacono D; Chiari R; Metro G; Bennati C; Bellezza G; Cenci M; Ricciuti B; Sidoni A; Baglivo S; Minotti V; Crinò L
    Lung Cancer; 2015 Mar; 87(3):211-9. PubMed ID: 25601484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for lung cancer: present and future.
    Aggarwal C
    Ann Palliat Med; 2014 Jul; 3(3):229-35. PubMed ID: 25841697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
    Kaderbhai CG; Boidot R; Beltjens F; Chevrier S; Arnould L; Favier L; Lagrange A; Coudert B; Ghiringhelli F
    Oncotarget; 2016 Apr; 7(17):24860-70. PubMed ID: 27027238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing for lung cancer.
    Wu K; Huang RS; House L; Cho WC
    Future Oncol; 2013 Sep; 9(9):1323-36. PubMed ID: 23980680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
    Kruglyak KM; Lin E; Ong FS
    Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.
    Azzato EM; Deshpande C; Aikawa V; Aggarwal C; Alley E; Jacobs B; Morrissette J; Daber R
    Anticancer Res; 2015 May; 35(5):3007-12. PubMed ID: 25964588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.